SIRT5-dependent desuccinylation licenses UBR5-mediated degradation of TAMM41 to regulate mitochondrial metabolism in lung adenocarcinoma

Lung adenocarcinoma (LUAD) is the most common form of lung cancer, and cancer cells heavily rewire their energy metabolism to survive and spread. This study focuses on TAMM41, a protein sitting in the inner membrane of mitochondria that is essential for building cardiolipin — a specialized fat molecule that holds the mitochondria's energy-generating machinery together. The researchers found that TAMM41 is unusually abundant in LUAD tumors compared with normal lung tissue, and patients whose tumors express high levels of TAMM41 tend to fare worse. When they switched TAMM41 off in cancer cells or in mouse tumor models, the cells lost their ability to produce energy efficiently, accumulated damaging oxidative stress, and died at higher rates. The team then traced the molecular chain of command: a sirtuin enzyme called SIRT5 removes a chemical tag (succinylation) from a specific site on TAMM41, which allows a protein-destruction machine called UBR5 to grab TAMM41 and send it for degradation. When SIRT5 activity is low — as it appears to be in LUAD — TAMM41 escapes destruction and accumulates, fueling tumor growth. The upshot is that the SIRT5–TAMM41–UBR5 pathway is a previously unrecognized control point in mitochondrial lipid metabolism that cancer cells exploit, making TAMM41 a candidate drug target in LUAD.

• TAMM41 protein is significantly upregulated in LUAD tumor tissues and cell lines relative to normal lung tissue, and high TAMM41 expression correlates with poor patient prognosis in clinical cohort analysis.
• Genetic ablation of TAMM41 suppresses LUAD cell proliferation, migration, and invasion in vitro, and markedly inhibits xenograft tumor growth in vivo, accompanied by impaired mitochondrial complex I activity, reduced ATP production, disrupted redox homeostasis, and increased apoptosis.
• SIRT5-mediated desuccinylation at lysine 45 of TAMM41 is required for UBR5 binding; UBR5 then ubiquitinates TAMM41 at lysine 206 to trigger proteasomal degradation — establishing a post-translational regulatory axis (SIRT5→desuccinylation→UBR5 ubiquitination→TAMM41 degradation) that controls cardiolipin biosynthesis and mitochondrial metabolic output in LUAD.

This is a preclinical mechanistic study combining in vitro and in vivo approaches. Human LUAD cell lines were used for loss-of-function experiments (TAMM41 knockout/knockdown) assessing proliferation, migration, invasion, mitochondrial respiration, ATP levels, ROS, and apoptosis. Protein–protein interaction and post-translational modification studies employed co-immunoprecipitation, mass spectrometry-based succinylation mapping, and ubiquitination assays to define the SIRT5–TAMM41–UBR5 axis. In vivo tumor growth was assessed using subcutaneous xenograft models in immunodeficient mice; clinical relevance was evaluated by correlating TAMM41 expression with prognosis in LUAD patient datasets.

As a purely preclinical study using cell lines and xenograft models, this work cannot establish whether TAMM41 inhibition would be safe or efficacious in patients, nor does it account for the immunological tumor microenvironment absent in immunodeficient xenograft hosts. The study does not test orthotopic or genetically engineered mouse models that better recapitulate spontaneous LUAD. Causality between SIRT5 downregulation and TAMM41 accumulation in primary human tumors remains correlative; direct pharmacological inhibition of TAMM41 or restoration of SIRT5 activity has not yet been demonstrated. Future work should validate the axis in patient-derived organoids or co-clinical trial specimens and assess whether cardiolipin depletion specifically — rather than broader mitochondrial disruption — is the dominant anti-tumor mechanism.

This article extends the sirtuin-PTM theme explored in [§29], which examines SIRT2-dependent deacetylation of tubulin to regulate mitochondrial function, by demonstrating that a distinct mitochondrial sirtuin (SIRT5) uses desuccinylation — rather than deacetylation — to control substrate stability and downstream organelle metabolism, illustrating how different sirtuin family members employ divergent PTM chemistries toward convergent mitochondrial outcomes. It parallels [§71], which frames mitochondrial dysfunction as a driver of disease progression (in polycystic kidney disease), reinforcing the emerging principle that organ-specific cancers and other chronic diseases co-opt shared mitochondrial regulatory nodes, albeit through distinct effector proteins. The cardiolipin-biosynthesis focus also parallels [§116], which tracks tissue-specific mitochondrial metabolic remodeling in an aldehyde dehydrogenase-deficient aging model, since both studies highlight how disruption of inner-membrane lipid or redox homeostasis cascades into broader bioenergetic failure. Taken together, the SIRT5–TAMM41–UBR5 axis described here adds a succinylation-gated ubiquitin-proteasome layer to mitochondrial quality control that is not addressed in any of the autophagy/mitophagy-centric articles in this corpus (e.g., [§134], [§136]), underscoring a complementary but mechanistically distinct route by which cells regulate mitochondrial composition.

• NMN/NAD+ enhances SIRT2-modulated microtubule dynamics to improve mitochondrial and mitophagy functions in senescent cells
  Both studies dissect sirtuin-dependent post-translational modifications that regulate mitochondrial function, but use different sirtuins (SIRT5 desuccinylation here vs. SIRT2 deacetylation) and different substrates, making direct comparison informative for understanding PTM-specific sirtuin biology.
• The Role of Mitochondria in Polycystic Kidney Disease
  Both articles position mitochondrial dysfunction as a central driver of disease progression in epithelial tissues (lung vs. kidney), enabling comparison of how organ-specific pathologies converge on shared mitochondrial vulnerabilities despite distinct molecular mechanisms.
• Impact of aldehyde dehydrogenase 2 deficiency on tissue-specific mitochondrial metabolism in aging mice
  Both studies interrogate how disruption of mitochondrial metabolic homeostasis — via lipid biosynthesis defects here vs. aldehyde detoxification failure there — produces tissue-specific bioenergetic consequences, providing a useful contrast between cancer and aging contexts.
• Heterogeneous Mitochondrial Gene Expression in SH-SY5Y Cells Following ERRa and ERRy Depletion Reveals Divergent Stress Responses
  Both articles investigate transcriptional and post-translational regulation of mitochondrial metabolism in disease (LUAD vs. neuroblastoma-derived SH-SY5Y cells), but through entirely different effectors (SIRT5/UBR5/TAMM41 vs. ERRα/ERRγ), offering a side-by-side view of how upstream regulators diverge while downstream mitochondrial stress responses converge.
• Inhibition of Mitochondrial Respiration Fragments ER Architecture and Remodels Organelle Contact Sites, as Revealed by FIB-SEM
  Both papers probe the consequences of impaired mitochondrial respiration on organelle architecture and inter-organelle communication, but from opposite directions — this study shows how a biosynthetic enzyme (TAMM41) sustains respiratory complex activity, while the comparator shows what happens to ER structure when respiration is pharmacologically blocked.